Watchdog: Biogenerics needed 'as quickly as possible'

As the FDA hashes out issues on regulating knockoffs of biotech drugs, or what the industry calls biosimilars, the consumer advocacy group Public Citizen makes a case in a Chicago Tribune story this week about the need for generic versions of pricey biologics. "Biotech drugs are among the world's most expensive," Sidney Wolfe, director of the health research group at Public Citizen, told the newspaper. "They have been good, but they have been expensive, so it is extraordinarily important to get biogenerics as quickly as possible." Article

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.